Journal
JOURNAL OF CELLULAR PHYSIOLOGY
Volume 236, Issue 4, Pages 2505-2518Publisher
WILEY
DOI: 10.1002/jcp.30062
Keywords
GPCRs; melatonin; somatostatin; targeted therapies; tumors
Categories
Funding
- Fondazione Giuseppe Di Bella Onlus
Ask authors/readers for more resources
Recent studies have shown that G protein-coupled receptors (GPCRs) are frequently mutated in various cancer types, posing significant challenges for targeted therapeutics. Among the molecules that activate GPCRs, somatostatin and melatonin play important roles in regulating tumorigenesis, offering potential for cancer therapy through modulation of signaling pathways.
Recent studies have shown that G protein-coupled receptors (GPCRs), the largest signal-conveying receptor family, are targets for mutations occurring frequently in different cancer types. GPCR alterations associated with cancer development represent significant challenges for the discovery and the advancement of targeted therapeutics. Among the different molecules that can activate GPCRs, we focused on two molecules that exert their biological actions regulating many typical features of tumorigenesis such as cellular proliferation, survival, and invasion: somatostatin and melatonin. The modulation of signaling pathways, that involves these two molecules, opens an interesting scenario for cancer therapy, with the opportunity to act at different molecular levels. Therefore, the aim of this review is the analysis of the biological activity and the therapeutic potential of somatostatin and melatonin, displaying a high affinity for GPCRs, that interfere with cancer development and maintenance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available